Skip to main content
SpringerLink
Log in

Hypertension

Surgery remains treatment of choice for CTEPH

  • News & Views
  • Published:

From Nature Reviews Cardiology

View current issue Sign up to alerts

The long-term outcomes of operated and nonoperated patients with chronic thromboembolic pulmonary hypertension were reported in a large, prospective, multicentre, European and Canadian registry. The long-term prognosis of operated patients was superior to that of nonoperated patients, indicating that surgery should be the first-choice treatment in this patient cohort.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Progress in the treatment of patients with chronic thromboembolic pulmonary hypertension.

References

  1. Madani, M. M. et al. Pulmonary endarterectomy: recent changes in a single institution's experience of more than 2,700 patients. Ann. Thorac. Surg. 94, 97–103 (2012).

    Article  Google Scholar 

  2. Delcroix, M. et al. Long-term outcome of patients with chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. http://dx.doi.org/10.1161/CIRCULATIONAHA.115.016522, (2016).

  3. Galiè, N. et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur. Respir. J. 46, 903–975 (2015).

    Article  Google Scholar 

  4. Kim, N. H. et al. Chronic thromboembolic pulmonary hypertension. J. Am. Coll. Cardiol. 62 (Suppl.), D92–D99 (2013).

    Article  Google Scholar 

  5. Riedel, M., Stanek, V., Widimsky, J. & Prerovsky, I. Longterm follow-up of patients with pulmonary thromboembolism: late prognosis and evolution of hemodynamic and respiratory data. Chest 81, 151–158 (1982).

    Article  CAS  Google Scholar 

  6. Saouti, N. et al. Predictors of mortality in inoperable chronic thromboembolic pulmonary hypertension. Respir. Med. 103, 1013–1019 (2009).

    Article  Google Scholar 

  7. Ghofrani, H. A. et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N. Engl. J. Med. 369, 319–329 (2013).

    Article  CAS  Google Scholar 

  8. Simonneau, G. et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). Eur. Respir. J. 45, 1293–1302 (2015).

    Article  CAS  Google Scholar 

  9. Mizoguchi, H. et al. Refined balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension. Circ. Cardiovasc. Interv. 5, 748–755 (2012).

    Article  Google Scholar 

  10. Roik, M. et al. Refined balloon pulmonary angioplasty driven by combined assessment of intra-arterial anatomy and physiology — multimodal approach to treated lesions in patients with non-operable distal chronic thromboembolic pulmonary hypertension — technique, safety and efficacy of 50 consecutive angioplasties. Int. J. Cardiol. 203, 228–235 (2016).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Anton Vonk Noordegraaf and Harm J. Bogaard are at the Department of Pulmonary Medicine, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, Netherlands.,

    Anton Vonk Noordegraaf & Harm J. Bogaard

Authors
  1. Anton Vonk Noordegraaf
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Harm J. Bogaard
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anton Vonk Noordegraaf.

Ethics declarations

Competing interests

A.V.N. declares that he receives lecture fees from Actelion, Bayer, Eli Lilly, GlaxoSmithKline, and Pfizer; is on the industry advisory board for Actelion and Bayer; and is serving on steering committees for Actelion, Bayer, and Pfizer. H.J.B. declares that he receives lecture fees from GlaxoSmithKline and Pfizer.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Noordegraaf, A., Bogaard, H. Surgery remains treatment of choice for CTEPH. Nat Rev Cardiol 13, 188–189 (2016). https://doi.org/10.1038/nrcardio.2016.30

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrcardio.2016.30

  • Springer Nature Limited

Search

Navigation